Patents by Inventor Cedric Kalinski

Cedric Kalinski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolidin-2-ones
    Patent number: 9045414
    Abstract: The present invention provides compounds of formula (I) or (Ia) which are ligands binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy and prevention. Compounds of formula (I) or (Ia) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's Disease, injury from ischemic events and heart valvular degenerative disease. Moreover, compounds of formula (I) or (Ia) can be used to decrease the side effects from cytotoxic cancer agents, radiation and to treat viral infections.
    Type: Grant
    Filed: January 17, 2012
    Date of Patent: June 2, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christoph Burdack, Cedric Kalinski, Vladimir Khazak, Gunther Ross, Lutz Weber
  • Tetrahydro-isoquinolines
    Patent number: 8367699
    Abstract: The present invention provides a compound selected from compounds of formula (A) as ligand binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy and prevention. Compounds of formula (A) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's Disease, injury from ischemic events and heart valvular degenerative disease. Moreover, compounds of formula (A) can be used to decrease the side effects from cytotoxic cancer agents, radiation and to treat viral infections.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: February 5, 2013
    Assignee: NexusPharma, Inc.
    Inventors: Lutz Weber, Vladimir Khazak, Gunther Ross, Cedric Kalinski, Christoph Burdack
  • NOVEL PYRROLIDIN-2-ONES
    Publication number: 20120122839
    Abstract: The present invention provides compounds of formula (I) or (Ia) which are ligands binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy and prevention. Compounds of formula (I) or (Ia) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's Disease, injury from ischemic events and heart valvular degenerative disease. Moreover, compounds of formula (I) or (Ia) can be used to decrease the side effects from cytotoxic cancer agents, radiation and to treat viral infections.
    Type: Application
    Filed: January 17, 2012
    Publication date: May 17, 2012
    Applicant: Priaxon AG
    Inventors: Christoph BURDACK, Cedric Kalinski, Vladimir Khazak, Gunther Ross, Lutz Weber
  • Pyrrolidin-2-ones
    Patent number: 8119623
    Abstract: The present invention provides compounds of formula (I) or (Ia) which are ligands binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy and prevention. Compounds of formula (I) or (Ia) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's Disease, injury from ischemic events and heart valvular degenerative disease. Moreover, compounds of formula (I) or (Ia) can be used to decrease the side effects from cytotoxic cancer agents, radiation and to treat viral infections.
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: February 21, 2012
    Assignee: Priaxon AG
    Inventors: Christoph Burdack, Cedric Kalinski, Vladimir Khazak, Gunther Ross, Lutz Weber
  • NOVEL PYRROLIDIN-2-ONES
    Publication number: 20100075949
    Abstract: The present invention provides compounds of formula (I) or (Ia) which are ligands binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy and prevention. Compounds of formula (I) or (Ia) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's Disease, injury from ischemic events and heart valvular degenerative disease. Moreover, compounds of formula (I) or (Ia) can be used to decrease the side effects from cytotoxic cancer agents, radiation and to treat viral infections.
    Type: Application
    Filed: September 15, 2009
    Publication date: March 25, 2010
    Inventors: Christoph BURDACK, Cedric KALINSKI, Vladimir KHAZAK, Gunther ROSS, Lutz WEBER
  • NOVEL TETRAHYDRO-ISOQUINOLINES
    Publication number: 20090306130
    Abstract: The present invention provides a compound selected from compounds of formula (A) as ligand binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy and prevention. Compounds of formula (A) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's Disease, injury from ischemic events and heart valvular degenerative disease. Moreover, compounds of formula (A) can be used to decrease the side effects from cytotoxic cancer agents, radiation and to treat viral infections.
    Type: Application
    Filed: September 14, 2007
    Publication date: December 10, 2009
    Inventors: Lutz Weber, Vladimir Khazak, Gunther Ross, Cedric Kalinski, Christoph Burdack